{"id":"W2766230215","doi":"10.1016/s0140-6736(17)32641-7","title":"Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":912,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary","funders":"Bristol-Myers Squibb","keywords":"Medicine; Adalimumab; Crohn's disease; Internal medicine; Prednisone; Azathioprine; Calprotectin; Randomized controlled trial; Infliximab; Disease; Clinical trial; Faecal calprotectin; Gastroenterology; Physical therapy; Inflammatory bowel disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008718992172745674,"score_gpt":0.2910485685363462,"score_spread":0.2823295763636005,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}